High‐dose nifuratel for simple and mixed aerobic vaginitis: A single‐center prospective open‐label cohort study. Issue 10 (19th July 2016)

• Record Type: Journal Article
• Authors: Liang, Qian; Li, Nan; Song, Shurong; Zhang, Aihua; Li, Ni; Duan, Ying
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 42:Issue 10(2016)
• Page Start: 1354
• Page End: 1360
• Publication Date: 2016-07-19
• Subjects: aerobic vaginitis -- bacterial vaginosis -- candidal vaginitis -- macmiror -- nifuratel -- trichomonas vaginitis; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.13052
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Aim: The efficacy and safety of two nifuratel dosages for the treatment of aerobic vaginitis (AV) were compared. Methods: This was a prospective open‐label cohort study of patients diagnosed and treated at the Tianjin Third Central Hospital between January 2012 and December 2013. The co‐presence of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), or/and trichomonal vaginitis (TV; mixed AV) was determined. Patients were randomized to nifuratel‐500 (500 mg nifuratel, intravaginal, 10 days) or nifuratel‐250 (250 mg nifuratel, intravaginal, 10 days), and followed‐up for three to seven days after treatment completion. Primary and secondary outcomes were recovery rate and adverse events, respectively. Results: The study included 142 patients with AV. Age was not significantly different between the groups ( n = 71 each), and disease distribution was identical: 29 (40.85%) simple AV and 42 (59.15%) mixed AV (AV + BV, 42.86 %; AV + VVC, 30.95%; AV + TV, 26.19%). In patients with simple AV, the recovery rate did not differ significantly between the nifuratel‐500 (26/29, 89.66%) and nifuratel‐250 (22/29, 75.86%) groups. In patients with mixed AV, recovery rates were significantly higher in the nifuratel‐500 than in the nifuratel‐250 group (AV + BV, 88.89% vs 50.00 %; AV + VVC, 76.92 % vs 30.77 %; AV + TV, 90.91 % vs 36.36%; all P < 0.05). Only one patient (nifuratel‐500) reported an adverse event (mild anaphylactic reaction). Conclusion: Nifuratel 500 mg showed good clinical efficacy for the treatment of AV, particularly mixed AV, and is superior to the 250 mg dosage in the treatment of mixed AV.